These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 8851598

  • 1. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
    Kumagai Y, Kato JI, Hoshino K, Akasaka T, Sato K, Ikeda H.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):710-14. PubMed ID: 8851598
    [Abstract] [Full Text] [Related]

  • 2. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Nishino Y, Ishihara S, Kawada Y.
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [Abstract] [Full Text] [Related]

  • 3. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M, Fukuda H, Yokoi S, Ishihara S, Kawada Y, Deguchi T.
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [Abstract] [Full Text] [Related]

  • 4. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.
    Vila J, Ruiz J, Goñi P, De Anta MT.
    Antimicrob Agents Chemother; 1996 Feb; 40(2):491-3. PubMed ID: 8834907
    [Abstract] [Full Text] [Related]

  • 5. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.
    Bagel S, Hüllen V, Wiedemann B, Heisig P.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):868-75. PubMed ID: 10103193
    [Abstract] [Full Text] [Related]

  • 6. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.
    Dessus-Babus S, Bébéar CM, Charron A, Bébéar C, de Barbeyrac B.
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2474-81. PubMed ID: 9756744
    [Abstract] [Full Text] [Related]

  • 7. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
    Chen JY, Siu LK, Chen YH, Lu PL, Ho M, Peng CF.
    Microb Drug Resist; 2001 Oct; 7(1):47-53. PubMed ID: 11310803
    [Abstract] [Full Text] [Related]

  • 8. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F.
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [Abstract] [Full Text] [Related]

  • 9. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.
    Heisig P.
    Antimicrob Agents Chemother; 1996 Apr; 40(4):879-85. PubMed ID: 8849244
    [Abstract] [Full Text] [Related]

  • 10. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS, Yague G, Fisher LM.
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [Abstract] [Full Text] [Related]

  • 11. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [Abstract] [Full Text] [Related]

  • 12. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EE, Cullen ME.
    Am J Med; 1989 Nov 30; 87(5A):2S-8S. PubMed ID: 2574005
    [Abstract] [Full Text] [Related]

  • 13. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.
    Bébéar CM, Grau O, Charron A, Renaudin H, Gruson D, Bébéar C.
    Antimicrob Agents Chemother; 2000 Oct 30; 44(10):2719-27. PubMed ID: 10991851
    [Abstract] [Full Text] [Related]

  • 14. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.
    Deguchi T, Fukuoka A, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Nishino Y, Ishihara S, Ban Y, Kawada Y.
    Antimicrob Agents Chemother; 1997 Mar 30; 41(3):699-701. PubMed ID: 9056017
    [Abstract] [Full Text] [Related]

  • 15. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.
    Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, Kawada Y.
    Antimicrob Agents Chemother; 1996 Apr 30; 40(4):1020-3. PubMed ID: 8849219
    [Abstract] [Full Text] [Related]

  • 16. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS, Fisher LM.
    Antimicrob Agents Chemother; 1997 Feb 30; 41(2):471-4. PubMed ID: 9021211
    [Abstract] [Full Text] [Related]

  • 17. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
    Ito H, Yoshida H, Bogaki-Shonai M, Niga T, Hattori H, Nakamura S.
    Antimicrob Agents Chemother; 1994 Sep 30; 38(9):2014-23. PubMed ID: 7811012
    [Abstract] [Full Text] [Related]

  • 18. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
    Kaneko A, Sasaki J, Shimadzu M, Kanayama A, Saika T, Kobayashi I.
    J Antimicrob Chemother; 2000 Jun 30; 45(6):771-5. PubMed ID: 10837428
    [Abstract] [Full Text] [Related]

  • 19. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.
    Breines DM, Ouabdesselam S, Ng EY, Tankovic J, Shah S, Soussy CJ, Hooper DC.
    Antimicrob Agents Chemother; 1997 Jan 30; 41(1):175-9. PubMed ID: 8980775
    [Abstract] [Full Text] [Related]

  • 20. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug 30; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.